Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis (CIPNM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01867645
Recruitment Status : Terminated (The trial was terminated early due to futility in reaching the primary endpoint.)
First Posted : June 4, 2013
Last Update Posted : June 4, 2013
Sponsor:
Collaborators:
Biotest Pharma GmbH
National Bank of Austria
Information provided by (Responsible Party):
Christian Madl, Medical University of Vienna

Brief Summary:
Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication of critical illness. Retrospective data suggest that early application of IgM-enriched intravenous immunoglobulin (IVIG) may prevent or mitigate CIPNM. Therefore, the primary objective was to assess the effect of early IgM-enriched IVIG versus placebo to mitigate CIPNM in a prospective setting.

Condition or disease Intervention/treatment Phase
Polyneuropathies Drug: IgM-enriched Intravenous Immunoglobulins Drug: Human Albumin Phase 1

Detailed Description:

Background: Critical illness polyneuropathy and/or myopathy (CIPNM) is a severe complication of critical illness. Retrospective data suggest that early application of IgM-enriched intravenous immunoglobulin (IVIG) may prevent or mitigate CIPNM. Therefore, the primary objective will be to assess the effect of early IgM-enriched IVIG versus placebo to mitigate CIPNM in a prospective setting.

Design: Prospective, randomized, double-blinded and placebo-controlled trial

Setting: Eight-bed medical ICU of a university hospital.

Participants: Critically ill patients will be screened for eligibility defined as multiple organ failure (MOF) and SIRS/sepsis. Patients fulfilling these criteria will be further assessed by a neurologist for clinical signs of CIPNM.

Critically ill patients with multiple organ failure (MOF), SIRS/sepsis, and early clinical signs of CIPNM will be randomized.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 38 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Impact of Early Treatment With IgM-enriched IVIG on Critical Illness Polyneuropathy and/or Myopathy in Patients With Multiple Organ Failure and SIRS/Sepsis: A Prospective, Randomized, Placebo-controlled, Double-blinded Trial
Study Start Date : December 2004
Actual Primary Completion Date : April 2009
Actual Study Completion Date : April 2011

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: IgM-enriched Intravenous Immunoglobulins
IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
Drug: IgM-enriched Intravenous Immunoglobulins
IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
Other Names:
  • IVIG
  • IgM-enriched IVIG

Placebo Comparator: Human Albumin
Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
Drug: Human Albumin
Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
Other Name: Placebo




Primary Outcome Measures :
  1. Effect of early IVIG versus placebo on CIPNM on day 14 [ Time Frame: day 14 ]
    The primary outcome was to assess the effect of early IVIG (IgM-enriched Intravenous immunoglobulins) versus placebo to mitigate CIPNM in critically ill patients as assessed by the CIPNM severity sum score on day 14. The CIPNM severity sum score is based on electrophysiological stimulation of the median, ulnar, and tibial nerves on days 0, 4, 7, 14 and on the histological evaluation of muscle biopsies on days 0 and 14 and ranged from 0 (no CIPNM) to 8 (very severe CIPNM).


Secondary Outcome Measures :
  1. Effect of early IVIG versus placebo on mortality from any cause within a 28-day period [ Time Frame: 28 days ]
    This secondary outcome aimed to assess the effect of early IVIG versus placebo on mortality from any cause within a 28-day period.

  2. Effect of early IVIG versus placebo on length of the ICU stay. [ Time Frame: ICU stay, an expected average of 30 days ]
    This secondary outcome aimed to assess the effect of early IVIG versus placebo on the length of the ICU stay. Length of ICU stay is defined as the time difference difference between admission of the patient to the ICU and discharge to a (non-ICU) ward or death. This outcome will be assessed an the day of ICU discharge.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Critically ill patients with failure of at least 2 organ systems diagnosed with SIRS or sepsis fulfilling the following inclusion criteria will be included in this study.

  1. Age Range: 18 - 80 years
  2. written information and consent as early as possible
  3. Male and female patients
  4. Clinical signs of incipient CIPNM:

    • decreased tendon reflexes as compared to the admission examination at the ICU
    • or weakness in responsive and co-operative patients as compared to the ad-mission examination at the ICU
    • or signs of incipient muscular atrophy as compared to the admission examination at the ICU

Organ failure:

Patients have to meet at least two of the following 5 criteria:

  • cardiovascular system dysfunction: arterial systolic blood pressure<90mm Hg, or mean arterial pressure < 70mm Hg for at least one hour despite adequate fluid resuscitation, adequate intravascular volume status or the use of vasopressors in an attempt to maintain a systolic blood pressure >90mm Hg or a mean arterial pressure >70mm Hg.
  • kidney dysfunction: Urine output < 0,5ml/kg body weight/ hour for 1 hour, despite adequate fluid resuscitation
  • respiratory system dysfunction: Ratio of PaO2 to FiO2 < 250 in the presence of other dysfunctional organs or systems
  • hematologic dysfunction: Platelet count <80.000/mm3 or decreased by 50% in the 3 days preceding enrollment (in the absence of liver cirrhosis or previously known hematological disease)
  • metabolic dysfunction: In case of unexplained metabolic acidosis - pH<7,30 or base deficit >5.0mmol/ litre in association with a plasma lactate level >1,5 times of the upper normal limit

SIRS:

Patients have to meet at least three of the following four criteria:

  • core temperature >38 or <36°C
  • heart rate >90 beats /min, except medical conditions known to increase heart rate
  • respiratory rate >20 breaths/min or a PaCO2 of <32mm Hg or the use of mechanical ventilation for an acute respiratory process
  • a white- cell count of>12.000 cells/mm3 or <4.000 cells/mm3 or a differential count showing >10% immature neutrophils

Sepsis:

Known or suspected infection evidenced by one or more of the following:

  • white cells or bacteria in a normally sterile body fluid
  • perforated viscus
  • radiographic evidence of pneumonia in the association with the production of purulent sputum
  • a syndrome associated with a high risk of infection

Exclusion Criteria:

The inclusion criteria have to be met at the time of enrolment into the study, i.e. at the start of the baseline period. Patients with any of the following conditions will be excluded from the study:

  1. Age < 18 years or > 80 years
  2. Weight >135 kg
  3. Pregnancy or breast-feeding
  4. Patients with known absolute IgA-deficiency with proven antibody formation against IgA
  5. Patients with known IVIG-intolerability
  6. Patients with known pre-existing neuromuscular disorders will not be included. Patients with documented pre-existing severe polyneuropathy will be excluded.
  7. Patients with known diseases of the peripheral nerval system and patients with pre-existing disease of the central nerval system with relevant impairment of the motor function.
  8. Patients with relevant pulmonary edema secondary to severe heart failure will be excluded because of the relatively high infusion volume (5ml /kg body weight per day over 3 days) determined by the study medication
  9. Patients not expected to survive 28 days because of uncorrectable medical condition, such as poorly controlled neoplasma or other end-stage disease
  10. Moribund state in which death is perceived to be imminent
  11. HIV infection in association with a last known CD4 count of<50/mm3
  12. Prediction, based on clinical judgement, that the patient will require chronic ventilatory support for non-respiratory reasons (e.g. neuromuscular disease, paraplegia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01867645


Locations
Layout table for location information
Austria
Medical University of Vienna
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Biotest Pharma GmbH
National Bank of Austria
Investigators
Layout table for investigator information
Principal Investigator: Christian Madl, MD Medical University of Vienna

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Christian Madl, Univ.-Prof.Dr., Medical University of Vienna
ClinicalTrials.gov Identifier: NCT01867645     History of Changes
Other Study ID Numbers: CIPNM
First Posted: June 4, 2013    Key Record Dates
Last Update Posted: June 4, 2013
Last Verified: May 2013

Keywords provided by Christian Madl, Medical University of Vienna:
Critical illness
Critical illness polyneuropathy and/or myopathy
Intravenous immunoglobulins
Multiple organ failure
SIRS
Sepsis

Additional relevant MeSH terms:
Layout table for MeSH terms
Sepsis
Critical Illness
Muscular Diseases
Polyneuropathies
Multiple Organ Failure
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes
Disease Attributes
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Peripheral Nervous System Diseases
Shock
Immunoglobulins
Antibodies
Immunoglobulins, Intravenous
gamma-Globulins
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs